University of California San Francisco

Alex Marson, MD, PhD

Alexander Marson, MD, PhD
Alex Marson, MD, PhD

Professor, Medicine
School of Medicine

Address

513 Parnassus Avenue HSE, #444
San Francisco, CA 94143
United States

Email: [email protected]

Education

Institution Degree Dept or School End Date
Harvard Medical School M.D. Medicine 2010
Massachusetts Institute of Technology (MIT) Ph.D. Biology 2008
University of Cambridge M.Phil Biological Sciences 2003
Harvard College A.B. Biology 2001

Awards & Honors

Award Conferred By Date
Elected Member of Association of American Physicians (AAP) 2022
CRI Lloyd J. Old STAR Career Award 2019
Elected Member of American Society of Clinical Investigators (ASCI) 2019
Chan Zuckerberg Biohub Investigator 2017
American Society of Clinical Investigation (ASCI) Young Physician-Scientist Award 2016
Burroughs Wellcome Foundation Career Award for Medical Scientists 2016
NIDA/NIH Avenir New Innovator Award 2016
Parker Institute for Cancer Immunotherapy, Project Member 2016

Grants and Funding

  • Transcriptional and post-transcriptional regulation of human Treg identity and function | NIH | 2026-02-06 - 2030-01-31 | Role: Principal Investigator
  • Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy | NIH | 2023-01-01 - 2027-12-31 | Role: Principal Investigator
  • Inherited T cell defects: Diagnosis, Mechanisms and Treatments | NIH | 2020-09-08 - 2025-08-31 | Role: Principal Investigator
  • Functional Molecular Investigation of Inflammatory Bowel Disease (IBD) Risk Variants | NIH | 2018-09-18 - 2022-05-31 | Role: Principal Investigator
  • Functional Interrogation of Non-Coding Type 1 Diabetes Risk Variants in Human Immune Cells and Beta Cells | NIH | 2016-09-30 - 2021-05-31 | Role: Principal Investigator
  • Functional Testing of Host Genes that control HIV Latency in Primary Immune Cells | NIH | 2016-06-01 - 2021-05-31 | Role: Principal Investigator

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma.
    Talbot A, Li K, Lee JHJ, Lang S, Liu C, Kalter N, Li Z, Mortazavi Y, Almudhfar N, Muldoon JJ, Allain V, Nyberg W, Chung JJ, Wang C, Qi Z, Krishnappa N, Ha AS, Kong D, Houser D, Paruthiyil S, Ahmadi M, Ji Y, Rosenberg M, Acevedo LA, Liang B, Briseno K, Kwek SS, Giannikopoulos P, Rivière I, Sadelain M, Oh DY, Marson A, Hendel A, Martin T, Eyquem J, Shy BR| | PubMed
  2. Systematic discovery of pro- and anti-HIV host factors in primary human CD4+ T cells.
    Rathore U, Dugan E, Thornton H, Kumar VE, Dajani R, Burdick RC, Young JM, Steinhart Z, Lao R, Delviks-Frankenberry KA, Choi W, Henriques WS, Echeverria I, Dann E, Dureja I, Pathak N, Arce MM, McKetney J, Umhoefer JM, Parulekar S, Schmidt R, Polacco BJ, Neidleman J, Montano M, Nguyen VQ, Sali A, Levy JA, Tenthorey JL, Cheng Y, Roan NR, Swaney DL, Kaake RM, Dodgson SE, Hiatt J, Pathak VK, Malik HS, Krogan NJ, Marson A| | PubMed
  3. Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells.
    Jung H, Devant P, Ching C, Ota M, Hamilton J, Steinhart Z, Ngo W, Sandoval L, Jung JH, Xu D, An M, Urs E, Chen PA, Allain V, Tada T, Nuñez JK, Landau NR, Liu DR, Eyquem J, Doudna JA, Marson A, Carnevale J| | PubMed
  4. Causal modelling of gene effects from regulators to programs to traits.
    Ota M, Spence JP, Zeng T, Dann E, Milind N, Marson A, Pritchard JK| | PubMed
  5. Gene-corrected regulatory T cell therapy for IL2RA deficiency.
    Ha AS, Kalter N, Rosenberg M, Acevedo LA, Liang B, Liu W, Paruthiyil S, Sinha M, Vu A, Nguyen V, Qi Z, Krishnappa N, Shu J, Yu J, Catanzaro J, Bluestone JA, Tang Q, Urnov FD, Marson A, Hendel A, Herold KC, Shy BR, Esensten JH| | PubMed
  6. FOXP3 expression depends on cell-type-specific cis-regulatory elements and transcription factor circuitry.
    Umhoefer JM, Arce MM, Kasinathan S, Whalen S, Dajani R, Subramanya S, Goudy L, Belk JA, Zhou R, Pham MTN, Zhang W, Hernandez R, Tran C, Kirthivasan N, Freimer JW, Mowery CT, Nguyen V, Ota M, Gowen BG, Simeonov DR, Curie GL, Li Z, Chen AY, Corn JE, Chang HY, Tang Q, Gilbert LA, Satpathy AT, Pollard KS, Marson A| | PubMed
  7. Site-specific DNA insertion into the human genome with engineered recombinases.
    Fanton A, Bartie LJ, Martins JQ, Tran VQ, Goudy L, Kernick C, Durrant MG, Wei J, Armour-Garb Z, Pawluk A, Konermann S, Marson A, Gilbert LA, Roth TL, Hsu PD| | PubMed
  8. Integrated epigenetic and genetic programming of primary human T cells.
    Goudy L, Ha A, Borah AA, Umhoefer JM, Chow L, Tran C, Winters A, Talbot A, Hernandez R, Li Z, Subramanya S, Arab A, Kale N, Lee JHJ, Muldoon JJ, Liu C, Schmidt R, Santangelo P, Carnevale J, Eyquem J, Shy BR, Marson A, Gilbert LA| | PubMed
  9. Base-editing a single missense mutation in A20 enhances CAR-T cell efficacy.
    Blaisdell A, Bachl S, Sandoval LR, Ching C, Bowman CJ, Kale N, Prabandham M, Diolaiti M, Havig C, Advincula R, Lenci N, Li Z, Yamashita E, Wang CH, Zhang S, Liu Q, Achacoso P, Stibor D, Øynebråten I, Seo J, Ashworth A, Marson A, Ye CJ, Malynn BA, Eyquem J, Carnevale J, Ma A| | PubMed
  10. Site-specific genome engineering of primary human natural killer cells for programmable anti-tumor function.
    Allain V, Rothrock AG, Bernard PL, Nyberg WA, Talbot A, Muldoon JJ, Chung JY, To A, Chang CR, Kimmerly GR, Liu C, Tsao T, Mortazavi Y, Seo J, Li Z, Shemesh A, Schmidt R, Ward CC, Marson A, Lanier LL, Aguilar OA, Eyquem J| | PubMed